Suven Life Sciences secures 2 product patents for NCE

Suven Life Sciences, a biopharmaceutical company has secured 2 Product Patents for their NCEs in the key markets in the world.

The company has reported a decent increase of about 26.16% in the sales to Rs. 45.65 crore for the quarter ended March 2011. The sales figure stood at Rs. 36.18 crore during the year-ago period. Net Profit for the quarter ended March 2011 zoomed to 121.44% from Rs 1.58 crore to Rs. 3.50 crore. Operating Profit margin saw a handsome growth to 11.84% from 7.09% in the quarter ended March 2011.

Suven Life Science focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. The Company has six internally-discovered therapeutic drug candidates currently, in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease. Parkinson's disease and obesity are in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.